GSK to buy Nuvalent for $10.6B [titlebase] in a Historic Deal, Expanding its Oncology Portfolio
admin floriparesort.com – 09 June 2026 | GSK has announced its plan to buy Nuvalent for $10.6B , a US-listed cancer drug developer, in an all-cash deal valued at approximately $10.6…